Navigation Links
AMT Provides Business Update for the Third Quarter 2009
Date:11/18/2009

AMSTERDAM, November 18 /PRNewswire-FirstCall/ --

- Glybera(R) Clinical Data Presented at Meeting of American Heart Association

Amsterdam Molecular Therapeutics (EuroNext Amsterdam: AMT), a leader in the field of human gene therapy, today provides its non-audited business update in compliance with the EU transparency directive. This report summarizes material events and AMT's financial position for the third quarter of 2009.

    Q3 2009 Highlights

    - Jorn Aldag joins AMT as Chief Executive Officer

    - Glybera(R) remains on track for filing for regulatory approval in next
      three months

Jorn Aldag appointed as Chief Executive Officer

On September 24, 2009 AMT announced that Jorn Aldag, previously President and CEO of Evotec AG, Germany, would join AMT as Chief Executive Officer as of October 05, 2009. Jorn Aldag holds business degrees from the European Business School and the Harvard Business School. He remains Chairman of Molecular Partners AG, Switzerland, a privately-held biotech company focused on the development of its proprietary DARPin scaffold technology and its proprietary pipeline. Mr. Aldag's appointment was approved by AMT's Extraordinary General Meeting of shareholders on November 4, 2009.

At the same time, Prof. Sander van Deventer stepped down as interim CEO. He will continue to contribute his expertise and experience to AMT as Chairman of the Scientific Advisory Board and Business Consultant.

Business Update

AMT's cash position(*) on September 30, 2009 amounts to EUR21.4 million compared to EUR25.0 million on June 30, 2009. The cash outflow in the third quarter of 2009, amounting to EUR3.6 million mainly represented operational cash flow and is well within the guidance for this period. The Company is adjusting its guidance for the year-end cash balance to approximately EUR17 milli
'/>"/>

SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Neuralstem, Inc. Reports Third Quarter Financial Results and Provides Business Update
2. Oncothyreon reports third quarter 2009 financial results & provides product pipeline update
3. Poniard Pharmaceuticals Reports Third Quarter 2009 Financial Results and Provides a Corporate Update
4. Microbix Biosystems Provides a Corporate Update
5. Alexandria Real Estate Equities, Inc. Provides Update
6. SemBioSys provides an update on Botaneco
7. MacuSight(R) Provides Clinical Development Update for Perceiva(TM)
8. New nanostructure technology provides advances in eyeglass, solar energy performance
9. Savient Provides Update on Meeting with U.S. Food and Drug Administration for KRYSTEXXA(TM)
10. Access Pharmaceuticals Provides Update on ProLindac(TM)Clinical Development Plan
11. PharmaNet Development Group Provides Financial Update and Announces Geographic Expansion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... , Sept. 29, 2014  The 12th ... officially kicks off September 29 at the John ... over Boston for a weeklong ... Cold Chain Global Forum is designed to cover the ... the modern cold chain, all temperature range products, GDP ...
(Date:9/29/2014)... 29, 2014  Perrigo Company plc (NYSE: ... has transferred a portfolio of preclinical research assets, ... of Elan Corporation plc, to drug discovery and ... agreement, Perrigo will receive an upfront payment in ... on any future sales derived from the portfolio. ...
(Date:9/29/2014)... , Sept. 29, 2014  Xcenda, the strategic ... global pharmaceutical sourcing and distribution service companies, recently ... consumption. This research was analyzed in an economic ... associated with an increase in life years and ... at population-level coffee consumption across the ...
(Date:9/29/2014)... 29, 2014 Westbridge Agricultural Products ... EC, a highly effective new tool for organic ... broad spectrum contact herbicide for post-emergent, non-selective weed ... non-food crops. The formulation is an emulsifiable concentrate ... Review Institute (OMRI) for use in organic food ...
Breaking Biology Technology:12th Cold Chain GDP & Temperature Management Logistics Global Forum Officially Kicks Off in Boston 2Perrigo Announces the Out-Licensing of Preclinical Assets to Imago Pharmaceuticals 2Perrigo Announces the Out-Licensing of Preclinical Assets to Imago Pharmaceuticals 3Perrigo Announces the Out-Licensing of Preclinical Assets to Imago Pharmaceuticals 4Coffee Consumption May Increase Survival and Reduce Healthcare Costs 2Coffee Consumption May Increase Survival and Reduce Healthcare Costs 3Westbridge Receives EPA Approval for Its New SUPPRESS™ Herbicide EC 2
... 29, 2012 Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: ... to sell, subject to customary closing conditions, $40 million of ... to purchase shares of its common stock (and the shares ... of the Series 15 Convertible Preferred Stock and exercise and ...
... and TARRYTOWN, New York, May 26, 2012 ... SNY ) and Regeneron Pharmaceuticals, Inc. (NASDAQ: ... a Phase 2 trial of SAR236553/REGN727 (Study 1003, ... SAR236553/REGN727 is a subcutaneously administered, fully-human antibody targeting ...
... known that a diet high in fat and extremely low ... But how the diet worked, and why, was a mysteryso ... called it "Epilepsy,s Big, Fat Miracle." Now, researchers ... an answer, linking resistance to seizures to a protein that ...
Cached Biology Technology:Cell Therapeutics Announces Institutional Investor to Purchase $40 Million of Convertible Preferred Stock and Warrants to Purchase Common Stock 2Cell Therapeutics Announces Institutional Investor to Purchase $40 Million of Convertible Preferred Stock and Warrants to Purchase Common Stock 3Cell Therapeutics Announces Institutional Investor to Purchase $40 Million of Convertible Preferred Stock and Warrants to Purchase Common Stock 4Cell Therapeutics Announces Institutional Investor to Purchase $40 Million of Convertible Preferred Stock and Warrants to Purchase Common Stock 5Cell Therapeutics Announces Institutional Investor to Purchase $40 Million of Convertible Preferred Stock and Warrants to Purchase Common Stock 6Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet 2Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet 3Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet 4Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet 5Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet 6Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet 7Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet 8Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet 9Reverse engineering epilepsy's 'miracle' diet 2Reverse engineering epilepsy's 'miracle' diet 3
(Date:9/29/2014)... DETROIT In order to support the world,s ... chemicals, polymers and more, new and more efficient ... team of researchers, including several from Wayne State ... of a new grant from the National Science ... Guided Design of Multicomponent Materials for Electrocatalytic Cascade ...
(Date:9/29/2014)... Scientists at Washington State University have concluded ... Smith apples may help prevent disorders associated ... first to assess these compounds in apple cultivars ... print edition of the journal Food Chemistry ... a good source of these nondigestible compounds but ...
(Date:9/29/2014)... Santos has presented Dr. Cristin Samper, president and ... prestigious Order of San Carlos. , The Order ... and military officers who have made outstanding contributions ... international relations. , An international authority on conservation ... to the Colombian Residence in New York to ...
Breaking Biology News(10 mins):Wayne State research aims to develop new, more efficient catalytic materials 2An apple a day could keep obesity away 2
... Interventional Radiology hailed the Sept. 11 decision by ... has oversight of the 24 recognized medical specialty ... for a new Dual Primary Certificate in Interventional ... and its member boards confirmed the benefit to ...
... JEJU, REPUBLIC OF KOREA (September 12, 2012) A ... biologically diverse place on earth, according to the Wildlife ... list of species found there. The announcement was ... gathering of conservationists meeting through Sept. 13 in Jeju, ...
... a man with apparent battle wounds and curvature of the ... the University of Leicester. The University of Leicester has ... King Richard III with Leicester City Council, in association with ... third week, has yielded dramatic findings of human remains which ...
Cached Biology News:Society of Interventional Radiology hails affirmation of specialty's role in patient care 2Society of Interventional Radiology hails affirmation of specialty's role in patient care 3Society of Interventional Radiology hails affirmation of specialty's role in patient care 4Amazing diversity documented in national park 2King Richard III search in new phase after 'discovery has potential to rewrite history' 2King Richard III search in new phase after 'discovery has potential to rewrite history' 3King Richard III search in new phase after 'discovery has potential to rewrite history' 4King Richard III search in new phase after 'discovery has potential to rewrite history' 5King Richard III search in new phase after 'discovery has potential to rewrite history' 6King Richard III search in new phase after 'discovery has potential to rewrite history' 7King Richard III search in new phase after 'discovery has potential to rewrite history' 8King Richard III search in new phase after 'discovery has potential to rewrite history' 9
The piston kit includes 2 pistons to service one F10 pump of a BioLogic DuoFlow workstation....
BD BioCoat Poly-D-Lysine/Laminin 100 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of poly-D-lysine and laminin....
BD BioCoat BD MatrigelTM Matrix 100 mm Culture Dishes for hepatocytes, tissue-culture treated polystyrene with a uniform application of MATRIGEL Matrix....
BD BioCoat Gelatin 100 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of gelatin....
Biology Products: